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ABSTRACT
Background: Coronary artery disease remains a major public 
healthcare problem worldwide and percutaneous coronary 
intervention with drug-eluting stents is the most frequent treat-
ment option for these patients. The objective of this study was 
to evaluate the rate of clinical events in up to 10 years of 
clinical follow-up of patients treated with drug-eluting stents. 
Methods: We prospectively enrolled patients with an indication 
for percutaneous coronary intervention despite their clinical or 
angiographic presentation. The primary endpoint consisted of 
the evaluation of the composite rate of major adverse cardiac 
events (cardiac death, non-fatal acute myocardial infarction 
or the need of ischemia-guided target-vessel revascularization) 
in the late clinical follow-up. Results: From 2002 to 2012, 
we included 1,632 patients with mean age of 64.3 ± 10.9 
years, 71.4% were male and 31.2% had diabetes mellitus. 
The angiographic and clinical success rates were 99.1% and 
96.7%, respectively. Follow-up was obtained in 95.8% of the 
eligible patients at a mean of 3.4 ± 2.6 years. The primary 
endpoint was observed in 246 patients (15.9%), with rates 
of cardiac death of 6.4%, myocardial infarction of 3.6% and 
target-vessel revascularization of 5.5%. Stent thrombosis was 
observed in 40 patients (2.4%). Conclusions: In this clinical 
practice experience the use of drug-eluting stents demonstrated 
favorable acute and long-term results in the treatment of a 
non-selected population of patients with coronary artery disease 
and variable degrees of clinical and angiographic complexity.
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intervention. Drug-eluting stents. Coronary thrombosis. 
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RESUMO
Resultados Tardios de Pacientes Submetidos  
a Implante de Stents Farmacológicos  
do Registro SAFIRA
Introdução: A doença arterial coronária continua sendo um 
dos maiores problemas de saúde pública da atualidade e a 
intervenção coronária percutânea com stents farmacológicos 
é a forma mais frequente de tratamento desses pacientes. O 
objetivo deste estudo foi avaliar a taxa de desfechos clínicos no 
seguimento clínico de até 10 anos dos pacientes tratados com 
stents farmacológicos. Métodos: Pacientes com indicação de 
ICP foram incluídos de forma prospectiva, independentemente 
do quadro clínico ou angiográfico de apresentação. O desfecho 
primário consistiu na avaliação da taxa de eventos cardíacos 
adversos maiores combinados (óbito cardíaco, infarto agudo 
do miocárdio não fatal ou necessidade de revascularização do 
vaso alvo guiada por isquemia) no seguimento clínico tardio. 
Resultados: No período 2002 a 2012, incluímos 1.632 paci-
entes, com idade de 64,3 ± 10,9 anos, 71,4% eram do sexo 
masculino e 31,2% portadores de diabetes mellitus. As taxas 
de sucesso angiográfico e clínico foram de 99,1% e 96,7%, 
respectivamente. O seguimento clínico foi realizado em 95,8% 
dos elegíveis em um tempo médio de seguimento de 3,4 ± 2,6 
anos. O desfecho primário ocorreu em 246 pacientes (15,9%), 
com taxas de óbito cardíaco de 6,4%, infarto do miocárdio de 
3,6% e revascularização do vaso alvo de 5,5%. A trombose 
do stent foi verificada em 40 pacientes (2,4%). Conclusões: 
Nesta experiência da prática clínica diária, a utilização dos 
stents farmacológicos demonstrou resultados clínicos favoráveis 
agudos e no longo prazo no tratamento de uma população 
não selecionada de pacientes com doença arterial coronária 
e graus variáveis de complexidade clínica e angiográfica.
DESCRITORES: Doença da artéria coronariana. Intervenção 
coronária percutânea. Stents farmacológicos. Trombose coronária. 
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Among the cardiovascular diseases, coronary artery disease (CAD) remains a major public health prob-lem worldwide. It is estimated that, in the United 
States, one in three adults, or 81 million people, have 
some form of cardiovascular disease, including more 
than 17 million with coronary artery disease and, among 
them, approximately 10 million with angina pectoris.1,2
Percutaneous coronary intervention (PCI), which has 
shown significant technological developments over the 
years, culminating with the advent of drug-eluting stents 
(DES), is currently the most widely used technique in the 
treatment of CAD.3-8 First used in lesions of low clinical 
and angiographic complexity, a gradual expansion of its 
indications to more complex lesions and patients has 
been observed, yielding clinical outcomes consistently 
superior to PCI with bare metal stents.9
However, there are few studies evaluating the long-
term follow-up of this technology,10,11 and, in particular, 
there are few data from the Brazilian population,12 
whose own cultural and social characteristics influence 
the adherence to treatment, and also due to its differ-
ent genetic composition, compared to populations of 
large registries from the United States and Europe.13,14
This study aimed to evaluate the long-term results 
(up to ten years) of an unselected patient cohort un-
dergoing DES implantation in a tertiary hospital in the 
state of São Paulo.
METHODS
This was a prospective, non-randomized study of 
consecutive patients with CAD, treated with at least 
one DES from July 2002 to August 2012 in Complexo 
Hospitalar, Real e Benemérita Associação Portuguesa 
de Beneficência, which includes São Joaquim and São 
José hospitals, Serviço Arie Cardiologia Intervencioni-
sta. The protocol for this project was approved by the 
Research Ethics Committee under No 778-12, and all 
participants signed the informed consent.
Patients referred for coronary artery bypass graft 
(CABG), regardless of clinical or angiographic status 
and who could be treated with DES devices available 
in the special material sector of the hospital were 
included. Patients with contraindications to the use of 
antiplatelet or anticoagulant medication specified by 
the pharmacological protocol or who refused to sign 
the consent form were excluded.
Antiplatelet therapy
The protocol included a combination of two anti-
platelet agents, acetylsalicylic acid (ASA) and clopidogrel, 
in loading doses of 200 mg and 300 mg, respectively, 
administered 24 hours before the procedure in elec-
tive cases. In acute coronary syndrome (ACS) in non-
premedicated patients, ASA was chewed at a dose of 
300 mg and a loading dose of 600 mg of clopidogrel 
was administered. After the appearance of ticagrelor 
and prasugrel, these medications have been incorpo-
rated for use in ACS, or in elective cases of greater 
angiographic complexity, with PCI performed ad hoc, 
in loading doses of 180 mg and 60  mg, respectively. 
The use of glycoprotein IIb/IIIa inhibitors was at the 
discretion of the surgeon.
After the procedure, ASA was maintained indefi-
nitely at a dose of 100 mg/day. The P2Y12 inhibitors 
clopidogrel (75 mg/day), ticagrelor (90 mg twice daily), 
or prasugrel (10  mg/day) were recommended for a 
minimum of one year.
Data collection and follow-up
Data were collected through a specific form use by 
the team and stored in a database especially dedicated 
to the Safety and efFIcacy of drug-eluting stents in a 
ReAl-world population (SAFIRA) registry. Patients were 
followed after discharge by phone interview conducted 
by a healthcare professional, or by medical appoint-
ment; these assessments were performed at 1, 6, and 
12 months, and then, annually.
Technical procedure 
After obtaining access, unfractionated heparin was 
administered at a dose of 100  U/kg. In patients that 
received glycoprotein IIb/IIIa inhibitors, the initial dose 
was 70 U/kg, in an attempt to keep the activated clot-
ting time between 200 and 250 seconds.
Pre- and post-procedure serial angiographic ana-
lyzes, including qualitative and quantitative assessments 
of coronary lesions, were performed. The acquisition of 
angiograms occurred after administration of intra-arterial 
isosorbide mononitrate 10 mg (unless if clinically con-
traindicated) and included two orthogonal projections, 
separated by at least 30°, attempting to avoid the over-
lapping of arteries and to optimize the visualization of 
the target lesion.
The procedure was monitored by visual analysis and 
by quantitative coronary angiography and, if necessary, 
the CAAS 2000 (Pie Medical Imaging BV of Maastricht, 
The Netherlands) program was used by trained techni-
cians. The scans were recorded at a speed of 15 frames 
per second on 35 mm films, or in DICOM® (Digital Ima-
ging and Communication in Medicine®) digital format 
and stored in CDR media.
The location of the target lesion in the coronary 
tree was defined according to the coronary segment 
involved: ostial, proximal, middle and distal, with the 
use of Coronary Artery Surgery Study (CASS), a coronary 
mapping system, as modified for the Bypass Angioplasty 
Revascularization Investigation (BARI) study.15
During implantation of DES, the authors aimed to 
obtain full coverage of the lesion treated, preventing 
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post-dilation damage from the stent edges and, in the 
case of implantation of two sequential stents, without 
leaving any space between devices, with 2-3  mm 
overlapping of its stems.
Definitions
Angiographic success was defined as the implanta-
tion of a stent in the target lesion with residual stenosis 
< 20%, with Thrombolysis in Myocardial Infarction 
(TIMI) III final flow in the absence of thrombi and 
arterial dissection. Clinical success was characterized 
as angiographic success associated with the absence 
of in-hospital major adverse clinical events.
Stent thrombosis was defined as any ischemic event 
related to thrombotic occlusion of the stent, classified 
as definite, probable, and possible, and, as to the 
temporal evolution, as acute, subacute, late, and very 
late, according to the Academic Research Consortium 
(ARC) definition.16
All deaths that occurred were considered as cardiac, 
unless a noncardiac cause could be clearly established. 
Acute myocardial infarction (AMI) was defined as an 
increase in CK-MB greater than three times the reference 
value, with or without appearance of new Q waves 
lasting > 0.04 second in two or more contiguous leads 
on the electrocardiogram. Urgent CABG was classified 
as an in-hospital unplanned surgery.
Target-lesion revascularization was defined as a 
reintervention caused by a recurrence of the lesion 
within the stent or in the segment, including the five 
mm proximal or distal to the prosthesis; target-vessel 
revascularization was defined as a percutaneous or 
surgical reintervention in the target vessel.
Bleeding complications were classified as major and 
minor according to the TIMI classification.17 Vascular 
complications included pseudoaneurysm, hematoma, 
arteriovenous fistulae, external bleeding, retroperitoneal 
hematoma, arterial thrombosis, abscess at the site of 
puncture, and mycotic aneurysm.
Study outcomes
The primary endpoint was the assessment of the 
combined rate of major adverse cardiac events (MACE) 
(cardiac death, non-fatal AMI, or need for target-vessel 
revascularization indicated by ischemia) during clinical 
follow-up. Secondary endpoints included an evaluation of 
individual components of the primary endpoint, success 
of the procedure, vascular and bleeding complications, 
stent thrombosis, probability of MACE-free survival at 
ten years, and identification of predictors of MACE, 
of its individual components, and of stent thrombosis.
Statistical analysis
Continuous variables were presented as mean and 
standard deviation, and categorical variables were 
presented as frequencies (number and percentage). The 
curves of cumulative event-free survival were estimated 
by the Kaplan-Meier method.
To determine independent predictors of MACE, of 
its components, and of stent thrombosis, the multivariate 
logistic regression model of Cox was used, including 
variables whose were p-values ≤ 15% in the univariate 
model. The results were presented with odds ratio and 
a confidence interval of 95%. The proportional hazards 
premise was confirmed by Schoenfeld residuals testing; 
no violations were found.
The analyses were performed by the statistical 
program STATA® (StataCorp Company – College Station, 
Texas, USA), version 12.
RESULTS
From July 2002 to August 2012, 1,632 patients 
were included, with mean age of 64.3 ± 10.9 years; 
71.4% were males, and 31.2% suffered from diabetes 
mellitus (9.9% of these were insulin users; Table 1).
TABLE 1 
Clinical characteristics
Characteristic n = 1,632
Age, years 64.3 ± 10.9
Male, n (%) 1,166 (71.4)
Hypertension, n (%) 1,308 (80.1)
Diabetes mellitus, n (%) 510 (31.2)
In use of insulin 161 (9.9)
Dyslipidemia, n (%) 1,091 (66.9)
Smoking status, n (%) 279 (17.1)
Family history of coronary artery 
disease, n (%) 
662 (40.6)
Previous myocardium infarct, n (%) 391 (23.9)
Previous percutaneous coronary 
intervention, n (%) 
316 (19.4)
Previous coronary artery bypass graft 
surgery, n (%) 
250 (15.3)
Chronic obstructive pulmonary 
disease, n (%) 
21 (1.3)
Peripheral vascular disease, n (%) 45 (2.8)
Chronic renal failure, n (%) 130 (8)
Left ventricular ejection fraction  
< 40%, n (%)
238 (14.6)
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Late results
The clinical follow-up was performed in 1,542 
patients (95.8% of those eligible). The mean follow-up 
was 3.4 ± 2.6 years (range, one month to ten years) 
(Figure 2).
With respect to clinical picture, 872 (53.4%) 
patients had stable angina; 373 (22.9%) were asymp-
tomatic – 87.1% had positive ischemic evidence, 366 
(22.4%) presented with ACS without ST elevation, and 
21 (1.3%) were in ACS with ST elevation. From the 
patients with ACS with no ST elevation, 197 (54%) 
were classified as high risk, 118 (32%) as moderate 
risk, and 51 (14%) as low risk.
Angiographic and procedural characteristics
The majority of the population consisted of patients 
with multiarterial involvement (61.4%), and the most 
frequently treated vessel was the left anterior descend-
ing artery (63.3%). Intervention in left main coronary 
artery was performed in 83 cases (3.4%), and of these, 
17 (1%) were not protected by previous CABG. More 
complex B2- and C-type lesions were present in 1,639 
(63.2%) of all cases (Table 2).
The most used approach was the femoral route, in 
973 cases (58%). The use of the transradial approach 
began in 2006, and was performed in 699 procedures 
(41%) and, from 2009, this technique has become 
the preferred access route in this service. The brachial 
approach was used in 17 cases (1%). Figure 1 shows 
the rate of utilization of femoral and radial approaches 
over time. 1,689 procedures were performed, lasting 
from 8 to 300 minutes (mean 47.8 ± 2.3 minutes), and 
the mean volume of contrast used was 138 ± 63.8 mL, 
ranging from 30 to 350 mL. 2,592 lesions were treated, 
with the use of 2,664 DES, and a mean of 1.03 stents/
lesion. In 963 lesions (37.1%), direct stenting was per-
formed without need for pre-dilatation.
The mean diameter of the stents used was 2.98 
± 1.25 mm, with a mean length of 18.8 ± 8.0 mm, 
and the mean final pressure of deployment was 14.8 
± 2.7 atm.
In-hospital results
The success of clinical and angiographic procedures 
was 99.1% and 96.7%, respectively. The combined 
endpoint of death, non-fatal AMI, and urgent CABG 
occurred in 40 (2.4%) cases, death in eight (0.5%), 
myocardial infarction in 29 (1.8%), and the need for 
urgent CABG in three (0.2%) patients. Major bleeding 
was observed in 21 procedures (1.2%), with 12 (0.7%) 
hematomata ≥ 5 cm and nine (0.5%) cases of drop in 
hemoglobin ≥  5 g/dL. 
Minor bleeding occurred in 26 (1.5%) cases, due 
to 21 (1.2%) hematomata < 5 cm, and in five (0.3%) 
patients a drop in hemoglobin < 5 g/dL was observed. 
Vascular complications occurred in 60 (3.5%) proce-
dures, with addition of more 13 cases of arteriovenous 
fistula (0.8%). 
The in-hospital stay ranged from one to 32 days, 
with a mean of 1.5 ± 1.4 days.
TABLE 2 
Angiographic and procedural characteristics
Characteristic
n = 1,689 
procedures/ 
2,592 lesions
Coronary artery disease extent, n (%) 
Monoarterial 630 (38.6)
Biarterial 556 (34.1)
Triarterial 446 (27.3)
Treated vessel, n (%) 
Left anterior descending artery 1,067 (63.3)
Right coronary artery 680 (40.2)
Left circumflex artery 618 (36.6)
Left main coronary artery 88 (5.2)
Non-protected left main coronary 
artery 
17 (1.0)
Venous/arterial graft 
Characteristics of the lesion, n (%) 
Thrombus 90 (5.2)
Moderate/major calcification 71 (2.7)
Restenosis 181 (6.9)
Bifurcation 124 (4.8)
Type of stents used, n (%) 166 (6.4)
Endeavor® Sprint 730 (27.4)
Cypher® 525 (19.7)
Taxus® 405 (15.2)
Xience V®/Promus 386 (14.5)
BioMatrix® 178 (6.7)
Promus Element® 146 (5.5)
Other 294 (11.0)
Direct implantation, n (%) 963 (37.1)
Final deployment pressure, mmHg 14.8 ± 2.7
Glycoprotein IIb/IIIa inhibitors, n (%) 21 (1.2)
Lesion length, mm 20.1 ± 6.9
Reference vessel diameter, mm 2.76 ± 0.68
Minimal lumen diameter, mm 
Pre 0.54 ± 0.32
Post 2.88 ± 0.46
Stenosis diameter, % 
Pre 80.3 ± 10.6
Post 1.0 ± 4.3
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(15.1%). The need for target-lesion revascularization oc-
curred in 71 patients (4.6%) and total mortality occurred in 
142 (9.2%) cases. Thirty-seven patients (2.4%) underwent 
CABG, and 27 (1.7%) underwent PCI in a different vessel.
Stent thrombosis was observed in 40 patients (2.4%) 
throughout the period of evolution. Definite or prob-
able stent thrombosis occurred in 18 patients (1.1%); 
its temporal distribution is summarized in Figure 2.
Figure 3 shows Kaplan-Meier curves for survival free 
of MACE, cardiac death, AMI, and target-vessel revas-
cularization, respectively, over ten years of follow-up.
Table 3 presents independent predictors of the 
combined endpoint of cardiac death, non-fatal AMI, 
and ischemia-guided target-vessel revascularization, of 
their individual components, and of stent thrombosis, 
identified by multivariate analysis.
DISCUSSION
The results of this study demonstrate that in the 
clinical practice, the use of DES for the treatment of 
CAD in patients with varying degrees of clinical and 
angiographic complexity is an effective and safe proce-
dure, providing favorable outcomes during in-hospital 
and late phases, similarly to the findings obtained by 
those initial randomized trials of DES.3-8
To the authors’ knowledge, this is one of two national18 
published trials presenting a clinical follow up of ten 
years’ duration of unselected patients treated with DES.
In the analysis of the clinical characteristics of this 
study, it was observed that the mean age (64.3 ± 10.9 
years) and the percentage of male patients (71.4%) were 
in agreement with previously published studies on 
DES.3-8,19-22 It is worth mentioning the fact that 31.2% of 
this population consisted of patients with diabetes mellitus, 
which is a higher index than those found in randomized 
trials3-8 and in some registries, as the Swedish Coronary 
Angiography and Angioplasty Registry (SCAAR)22 (23.8%), 
and RESEARCH23 (22%); this value, however, is in agree-
ment with the REAL10 study from Emilia Romagna, Italy 
(30.7%).
PCI in the unprotected left main coronary artery 
was performed only in 17 patients (1.0%) in the pres-
ent study, and this scenario was also seen in DESIRE 
registry,18 which analyzed 4,229 patients undergoing DES 
implantation, showing that a lesion in that vessel was 
present in 1.5% of treated cases. The findings of these 
two centers are in agreement with the Central Nacional 
de Intervenções Cardiovasculares (CENIC) database,24 in 
which a total of 67,887 PCIs conducted from 2009 to 
2011 were registered, and only 1,081 (1.6%) of them 
were performed for the treatment of lesions located in 
the left main coronary artery, demonstrating that, in 
Brazil, the percutaneous treatment of this condition is 
still reserved for a limited number of patients.
Year
Figure 1 – Temporal evolution of the use of radial and femoral routes. 
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Figure 2 – Major adverse clinical events and stent thrombosis in 
late follow-up. AMI, acute myocardial infarction; TVR, target-vessel 
revascularization. 
The combined endpoint of cardiac death, non-fatal 
AMI, and ischemia-guided target-vessel revascularization 
(primary endpoint) occurred in 245 patients (15.9%); the 
combined endpoint of cardiac death, non-fatal AMI, and 
target-lesion revascularization occurred in 234 patients 
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The in-hospital results obtained in this series dem-
onstrate that in current clinical practice, the implemen-
tation of PCI is a safe procedure with a high rate of 
clinical and angiographic success. In fact, the use of 
coronary stents has provided better immediate results; 
indeed, their use corrected some important limitations 
of the coronary angioplasty with balloon catheter, such 
as acute vessel occlusion and dissections of the arterial 
wall. In this study, an emergency surgery was necessary 
only in 0.2% of cases.
Major bleeding occurred in 1.2% of patients – less 
than the rate found in patients treated with the femoral 
technique (2.3%) in the meta-analysis by Jolly et al.,25 
which analyzed 23 randomized trials (six diagnostic 
trials) that compared radial and femoral routes.
This fact reinforces the findings on the use of radial 
access as an important factor in reducing this kind of 
complication.
The clinical follow-up of ten years (mean 3.4 ± 
2.6 years) of this study’s population showed that the 
primary outcome of this study (cardiac death, non-fatal 
AMI, and ischemia-guided target-vessel revascularization) 
occurred in 15.9%. Tu et al.,26 in an analysis of 3,751 
patients undergoing DES implantation performed in the 
province of Ontario, Canada, observed, at the end of 
two years, an incidence of 17.4% for these events. 
In another important registry, the REAL10 study, which 
included 3,064 patients who underwent DES implanta-
tion with two years of follow-up, this rate was 20.2%.
Total stent thrombosis occurred in 2.4% of the 
present patients, and thromboses classified as definite 
or probable reached 1.1% of cases. In the study by 
Marzocchi et al.,10 angiographically proven thrombosis 
occurred in 1% of patients. Conversely, Costa Jr. et 
al.12 reported an overall incidence of 1.6% in a total 
of 2,365 patients analyzed, and in 1% of their cases, 
the thrombosis was classified as definite. 
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Figure 3 – Rates of survival free of major adverse cardiac events (MACE), cardiac death, acute myocardial infarction (AMI), and target-vessel revas-
cularization, respectively, over ten years of follow-up.
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In the present series, the curves of event-free sur-
vival over a period of up to ten years showed favorable 
results with the use of DES in clinical practice (67.2% 
of MACE, 84.2% of cardiac death, 86.2% of non-fatal 
AMI, and 81.8% of target-vessel revascularization). 
In the findings through five years of follow-up in the 
DESIRE registry, these rates were 91.5% for MACE-free 
survival and 96.7% for target-lesion revascularization-
free survival.11
Using multivariate analysis, seven independent 
predictors of MACE were identified. Of these, three 
(peripheral vascular disease, chronic renal failure, and 
off-label lesions/saphenous vein bypass graft) were also 
mentioned in the study by Sousa et al.,19 over a follow-
up period of up to ten years. Among the significant 
predictors of cardiac death, it is worth mentioning 
the use of the Taxus® stent, with a hazard ratio = 1.6 
(p  =  0.04). Stettler et al.20 conducted a meta-analysis 
involving 38 randomized trials with 18,023 patients and 
found no difference in the total mortality between bare 
metal stents and sirolimus- or paclitaxel-eluting stents.
However, the sirolimus-eluting stent showed a 17% 
relative reduction in the rate of AMI, compared to the 
paclitaxel-eluting stent (p = 0.05). Peripheral vascular 
disease was also a predictor of AMI (hazard ratio = 
3.77), a finding that was also observed in the analysis 
by Sousa et al.19 Regarding target-vessel revasculariza-
tion, the present study identified, as predictors, lesions 
located in the left main coronary artery and patients 
with history of previous AMI.
TABLE 3 
Independent predictors of major adverse cardiac events (MACE), death, acute myocardial infarction (AMI),  
target-vessel revascularization, and stent thrombosis
Variable Odds ratio 95% CI p-value
MACE 
Peripheral vascular disease 2.14 1.23-3.73 0.01
Chronic renal failure 2.01 1.32-3.07 0.01
Left main coronary artery 1.99 1.04-3.79 0.04
Saphenous vein 1.96 1.14-3.35 0.01
Previous AMI 1.51 1.10-2.06 0.01
Multivessel 1.45 1.06-1.98 0.02
Age 1.01 1.00-1.03 0.02
Death 
Chronic renal failure 3.78 2.26-6.34 < 0.01
Saphenous vein 2.47 1.21-5.07 0.01
Peripheral vascular disease 2.25 1.12-4.41 0.02
Calcification 1.87 1.23-2.83 0.01
Diabetes mellitus 1.82 1.19-2.76 0.01
Taxus® stent 1.60 1.03-2.50 0.04
Left ventricular dysfunction, moderate/severe 1.41 1.11-1.81 0.01
Age 1.06 1.04-1.08 < 0.01
AMI 
Peripheral vascular disease 3.77 1.34-10.60 0.01
Female gender 2.38 1.06-5.34 0.04
CABG 
Left main coronary artery 2.88 1.17-7.12 0.02
AMI 1.73 1.07-2.78 0.02
Stent thrombosis 
Peripheral vascular disease 5.02 2.03-12.36 < 0.01
Chronic renal failure 3.14 1.35-7.31 < 0.01
Age 1.04 1.01-1.07 0.02
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With respect to stent thrombosis, the predictors were: 
peripheral vascular disease, chronic renal failure, and 
age. The study by Iakovou et al.,21 which analyzed 2,229 
patients undergoing DES implantation in three European 
centers, demonstrated that, in addition to the chronic 
renal failure observed in the present study, diabetes 
mellitus, bifurcation lesions, premature discontinuation 
of antiplatelet therapy, and low left ventricular ejection 
fraction were independent predictors of stent thrombosis.
In the present study, a trend towards a higher rate 
of thrombosis with the paclitaxel-eluting stent, compared 
with sirolimus-eluting stent (0.8% vs. 1.7%; p = 0.09) 
was observed. This finding is in agreement with findings 
in the meta-analysis by Stettler et al.,20 which observed 
a relative increase of 86% in late definite thrombosis 
with the paclitaxel-eluting stent, compared with the 
sirolimus-eluting stent (p = 0.0041).
CONCLUSIONS
In this experience of patients in clinical practice, the 
use of drug-eluting stents demonstrated both favorable 
acute and long-term clinical outcomes for an unselected 
population of subjects with varying degrees of clinical 
and angiographic complexity. These findings, together 
with previous studies, have proven the efficacy and 
safety of this technology for the treatment of coronary 
artery disease.
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